论文部分内容阅读
一、厚生省造血障碍研究班的治疗方针1.再生障碍性贫血再障的诊断标准于1973年确定,并进行了重度分类。骨髓生成低下,白细胞总数500/mm~3以下,血小板数20000/mm~3以下,网织红细胞总数2000/mm~3以下3项中,有2项者为重症。白细胞总数500～1000,血小板数20000～50 000,网织红细胞总数20000～60000中,有2项者为中度。以外的为轻症。对轻症以支持疗法为主,配合雄激素疗法。对重症72例、中度症34例施行甲基泼尼松龙大剂量疗法,对107例重症施行抗胸腺球蛋白(ATG)、抗淋巴细胞球蛋白(ALG)疗法。按性别、年龄、重症度分组,与历史对照组比较,疗效无统计学意义。免疫抑制疗
First, the treatment of hematopoietic disorders research class treatment guidelines 1. Aplastic anemia, aplastic anemia diagnostic criteria set in 1973, and carried out a heavy classification. Bone marrow production is low, the white blood cell count 500 / mm ~ 3 the following, the number of platelets 20000 / mm ~ 3 the following, reticulocyte total number 2000 / mm ~ 3 the following three, two are critically ill. Leukocytes 500 ~ 1000, platelets 20000 ~ 50 000, the total number of reticulocytes 20000 ~ 60000, two were moderate. Other than mild. Support for mild to the main therapy, with androgen therapy. Thirty-seven patients underwent severe anti-thymocyte globulin (ATG) and anti-lymphocyte globulin (ALG) therapy in 34 patients with severe disease and 34 moderate disease patients undergoing high-dose methylprednisolone therapy. By gender, age, severity grouping, compared with the historical control group, the effect was not statistically significant. Immunosuppressive therapy